PVAG-14 a Potential New Regimen for Early-Stage Unfavorable Hodgkins

The era of refining combination chemotherapy treatment for Hodgkin's Lymphoma seems never-ending.

Reporting at the annual congress of the European Hematology Association, Dr. Diana Wongso, on behalf of the German Hodgkin's Study Group, explained that a new regimen, PVAG-14 (prednisone, vinblastine, doxorubicin and gemcitabine gave patients better tumor control with a lot less toxicity in patients diagnosed with early-stage unfavorable Hodgkin's, and that it might offer a better alternative to the 2 + 2 chemotherapy normally prescribed for this patient population.

In the study, 40 out of 41 patients achieved complete remission with PVAG-14 therapy. Compare that to the researchers' hopes that as many as half the participants achieve complete remission.

Although a very small trial, the results give researchers hope that this chemotherapy regimen could provide high tumor control with significantly less toxicity. "PVAG-14 might be an effective and less toxic alternative to 2+2 chemotherapy and should be tested in a phase III trial," said Dr. Wongso.

By "2+2 chemotherapy", Dr. Wongso is referring to the tendency among some clinical practice guidelines to recommend two cycles of ABVD and two cycles of BEACOPP for patients with early-stage unfavorable Hodgkin's, a regimen regarded to be unnecessarily toxic.

Median age among patients was 38 years. These results were presented at a medical conference and should be considered preliminary until published in a peer-reviewed journal.

Source: Oncologypractice.com

lymphoma roundup

More Articles

More Articles

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...